It is genuinely hard to believe that anyone thinks a public health program can benefit from a change that encourages pricing manipulation which in virtually any other Australian market would potentially be considered a breach of competition law. …
Could this change be the worst in the history of this program?
August 24, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Sanofi treatment for ultra-rare ASMD to be made available through LSDP
October 22, 2025 - - Latest News -
Sigma reports strong growth and upgraded synergies in first full year post-merger
October 22, 2025 - - Latest News -
IDT Australia sharpens strategy with cost savings and radiopharmaceutical focus
October 21, 2025 - - Latest News -
FOI reforms set back transparency decades and will impact public health decision-making
October 21, 2025 - - Latest News -
Astellas' XTANDI achieves landmark survival milestone in prostate cancer
October 21, 2025 - - Latest News -
Services Australia reports record number of processed PBS prescriptions
October 21, 2025 - - Latest News -
Endometriosis diagnoses in Australian GP clinics nearly double over a decade
October 21, 2025 - - Latest News